ADMA Biologics is trading at $10.57 (-4.82%), and the reason for the November 4 decline remains unclear. - No confirmed company-specific announcement explaining the decline was found in available coverage. - The company scheduled Q3 2026 results for after the November 4 market close; they remained pending at 3:02 p.m. ET. - Major indexes and biotech were rising, so neither clearly explains the stock’s drop.